Index

Note: Page numbers in italics refer to Figures; those in bold to Tables.

A4GALT gene, 61
ABCG2, ABCB6, 64
ABH secretion, 31, 31–2
FUT1 and FUT2, 32
haemagglutination-inhibition tests, saliva, 31, 31
ABO blood groups
ABH secretion, 31, 31–2
A₁A₂BO phenotype
frequencies, selected populations, 24, 24
indigenous British population, 24, 25
acquired B, 33
acquired changes, 33–4
acute myeloid leukaemia, 33
anti-A and -B, 25–6
A₁ and A₂ phenotypes, 23, 23–4
anti-A, B, 25–6, 102–3
antigens see antigens, ABO system
associations, disease and functional aspects, 34
biosynthetic pathways, A and B production, 28, 29
checklist, discrepancies, 93–4, 94
complexities, 32–3
discovery, 3, 4
exoglycosidases, 34
frequencies, phenotype and gene, 24, 24–5, 25
glycosyltransferases, 29, 28–30
H antigen, 30, 30–31
H-deficient red cells, 32
titration, 107
transfusion and transplantation medicine, 26–7
typing discrepancies, 92, 92, 93–4
acetylcholinesterase, 61
acute myeloid leukaemia, 33
ADCC see antibody dependent cell-mediated cytotoxicity (ADCC)
ADP-ribosyltransferase, 62
agglutination
direct, 11–12
indirect, 12–18, 13, 14–18
AHG see anti-human globulin (AHG)
AIHA see autoimmune haemolytic anaemia (AIHA)
alloimmunisation
passive anti-D differentiation, anti-D, 104
post-transfusion incidence, 105
ALeα, 60
2-aminoethylisothiouronium bromide (AET), 49
antibodies
alloimmunised pregnancy, tests, 77–8
antigen negative incidence,
specificity, 106
autoantibodies, 77
decision-making, transfusion, 78–80,
HDFN see haemolytic disease of the
fetus and newborn (HDFN)
HTRs see haemolytic transfusion
reactions (HTRs)
identification procedure, 13, 95
IgG subclasses, properties, 67, 69, 69
IgM antibodies, pentamer structure,
67, 68
in vivo destruction of red cells, 78
immunohaematology, 65
monoclonal, 66, 67
polyspecific, 66, 67
properties, immunoglobulins, 66, 68
screening, 105
specificity
and clinical significance, 70, 72
screening and identification,
69–70, 70
serological crossmatching (XM),
70, 71
titration, 107
antibody dependent cell-mediated
cytotoxicity (ADCC), 74, 78
antibody investigations, 98–101, 104
anti-D reagents, RhD typing, 103
antigen density
antigen-antibody reactions, 9–10
Rh antigens, 40, 40
antigen–antibody reactions
density, 9–10
pH, 9
temperature, 8–9
time and ionic strength, 9
antiglobulin tests
automated procedures, 14
control, 103–4
DAT, 14, 15
IAT, 14, 14
individual microtube, gel test, 18, 18
NISS and LISS, 15
non-routine IAT, 18
no-wash ID system, 16–17, 17
serum-to-cell ratio, 18
solid phase microplate methods, 16, 17
‘spin-tube’ method, IAT, 16, 16
anti-human globulin (AHG)
neutralisation, 17
‘no-wash’ ID-System, 16–17, 17
polyspecific, 14
solid phase microplate method, IAT, 16, 17
AnWj, 61
Au⁺, Au⁻, 61
capillary method, 77
auto-analyser technique, 77–8
autoantibodies, 77
autoimmune haemolytic anaemia
(AIHA), 18–19, 77
automated methods, routine blood
grouping, 8, 14, 19
band 3, 38–9, 39, 57–8, 58, 62
‘bed-side’ testing, 109
Bg antigens, 64
BLe⁺, 60
cardiac surgery, 109
blood groups
antibodies see antibodies
antigens, 1, 3–4
biological importance, 3–4
clinical importance, 3
definition, 1
proteins and glycoproteins, 2, 2
terminology and classification, 4–7,
transfusion and transplantation, 3
Bombay phenotype, 32
C4, 62
CAPA see corrective and preventive
action (CAPA)
C, c, E and e antigens (RH2, RH4, RH3,
RH5)
clinical significance, antibodies, 45
frequencies, populations, 44–5, 45
molecular basis, C/c and E/e
polymorphisms, 45
CD35, 63
CD44, 63
Index

CD55, 63
CGD see chronic granulomatous disease (CGD)
chemiluminescence test (CLT), 74, 78
chemokines, and Duffy-glycoprotein, 53–4
Chido/Rodgers system, 4, 5, 62
chronic granulomatous disease (CGD), 52
cisAB phenotype, 33
CLT see chemiluminescence test (CLT)
Co⁺, Co⁺, Co⁺, 62
cold haemagglutinin disease, 63
Colton system, 5, 62
complement cascade activation, MAC, 65, 66
compound antigens and antibodies, 46, 105–6
corrective and preventive action (CAPA), 89–91, 90
CR1, 63
Cromer system, 5, 63
cross-matching, 95, 98
electronic, 108
immediate spin, 108
C⁺, 46
C⁺, 46
cytoskeleton, 39, 39

D (RH1)
antibodies
clinical significance, 42–4
passive, 104
antigen sites, 40, 45
frequencies, 40
molecular basis, 40
protein, 39, 39
testing, 44, 44, 103–4
variants
DEL, 41
exons of RHD, 43
partial D, 41, 103
symbols, 41, 42
weak D, 41, 103
DAT see direct antiglobulin test (DAT)
decay accelerating factor, 63
Di⁺, Di⁺, 58
Diego system, 5, 57–9, 58
low frequency antigens, 59
direct agglutination, 11–12, 12
direct antiglobulin test (DAT)
molecular tests, 83
sensitisation, red cells in vivo, 14, 15
DISK, 59
dithiothreitol (DTT), 49, 98, 101
DNA
ABO typing, 83–4
fetal, 81–2
molecular test, 82–3
next generation sequencing, 84
SNPs, 82
transfusion-dependent patients, 83
Do⁺, Do⁺, 62
DOLG, 62
DOMR, 62
DOYA, 62
Dombrock system, 4, 5, 62
droppers, 106
Duffy antigen receptor for chemokines (DARC) see Duffy-glycoprotein
Duffy-glycoprotein, 53–4, 54
Duffy system, 5, 52–4, 53, 54
Duffy-glycoprotein, 53–4, 54
and malaria, 54

E and e antigens see C, c, E and e antigens
EDTA see ethylenediaminetetraacetic acid (EDTA)
EKLF1, 61
‘electronic crossmatch’, 108
electronic issue, blood, 108–9
elution techniques, 18–19
enzyme–antiglobulin test, 18
enzyme techniques
neuraminidase, 12
treatment effects, red cells, 13, 13
ERMAP, 61
weight-for-volume method, 13
fetal blood grouping, 81–2
fetomaternal haemorrhage (FMH), 19–20
flow cytometry
   cells/‘events’, 20
   FMH, 19–20
   principle, 20, 20
FMH see fetomaternal haemorrhage (FMH)
Forssman system, 6
Fya, Fyb, Fy3, Fy5, 52–3
G antigen, 46
GATA-1, 61
gel test, 16, 18
gene conversion, 57
genotyping, 81–4
Gerbich system, 5, 62
Gill system, 6
Globoside system, 6
glycolipids, 1
glycophorin A (GPA), 56
glycophorin B (GPB), 56–7
glycophorin C (GPC), 62
glycophorin D (GPD), 62
glycoproteins, 1, 2
glycosylphosphatidylinositol (GPI) anchor,
   ‘gold standard’ test, 102
GPA see glycophorin A (GPA)
GPB see glycophorin B (GPB)
GPC see glycophorin B (GPC)
GPD see glycophorin B (GPD)
GPI anchor see
glycosylphosphatidylinositol (GPI) anchor
Gy*, 62

HA see haemolytic anaemia (HA)
haemagglutination, 11, 12
   inhibition techniques, 31
haemolytic anaemia (HA), 65, 77
haemolytic disease of the fetus and newborn (HDFN)
antenatal care, alloimmunised pregnancy, 73, 74
anti-D, 40, 42, 43
anti-G, 46
anti-K, 51
Colton antibodies, 62
crossmatching, infants under 4 months old, 77
definition, 3
IgG antibodies, 73
   in vitro tests, 74
interventions, alloimmunised pregnancies, 75, 76
IUT, 73, 76
kernicterus, 75
Rh antibodies, 45
severe ABO, 26
transplacental haemorrhage,
amniocentesis, 81
haemolytic transfusion reactions (HTRs)
   anti-Fya and anti-Fyb, 53
   anti-H, 32
   avoidance, 110
   blood group antibodies, 3
   extravascular red cell destruction,
   72–3
   intravascular red cell destruction,
   72, 72
Kidd antibodies, 54
   symptoms, 26, 109
   Vel antibodies, 64
   haemovigilance systems, 109–10
H antigen, 30, 30–31
H-deficient red cells, 32
HDFN see haemolytic disease of the fetus and newborn (HDFN)
   high-titre haemagglutinins, 108
   histo-blood group antigens, 22
   HJK, 64
HTRs see haemolytic transfusion reactions (HTRs)
   human leukocyte antigens, 64
   Hy, 62
IAT see indirect antiglobulin test (IAT)
   immediate spin (IS), 108
I and I antigens, 63
IgA, 68
IgD, 68
IgE, 68
IgG, 3, 68, 68 subclasses, 69
IgM, 3, 68, 68
ionic strength, antigen-antibody
reactions, 9
immunoglobulin superfamily, 61, 62
Inγ, Inβ, 63
Indian system, 5, 63
indirect agglutination
antiglobulin tests, 14–18
enzyme techniques, 12–13, 13
indirect antiglobulin test (IAT)
blood group antibodies detection,
serum, 14, 14
LISS, 15
Intercellular adhesion molecule-4
(ICAM-4), 62
International Society of Blood
Transfusion (ISBT)
terminology and classification, 4–7,
5–7
intrauterine transfusions (IUT), 73, 76
IS see immediate spin (IS)
ISBT see International Society of Blood
Transfusion (ISBT)
I system, 6
IUT see intrauterine transfusions (IUT)

JFV, 64
Jkα, Jkβ, Jk3, 54–5, 55, 55
Jk(a–b–) phenotype, 55
Joγ, 62
John Milton Hagen (JMH) system, 6
JONES, 64
Jrα, 64
JR system, 6, 64
Jsα, Jsβ, 50, 51
K, k, 50
Kell system
antibodies, 51
antigens, 50–51
antithetical antigens, 50

glycoprotein and KEL gene, 49–50
K, phenotype, 51
Kx (KX1), 52
McLeod syndrome and phenotype,
52
Kg, 59
Kidd-glycoprotein, 55, 55–6
Kidd system
Jkα and Jkβ antigens frequencies,
populations, 54, 55
Jk(a–b–) and Jk3, 55
Kidd-glycoprotein, 55, 55–6
Knops system, 5, 63
Kpα, Kpβ, Kpγ, 50–51
Kx system, 4, 5, 52
Laboratory errors, 89–91
Landsteiner’s rule, 23
Landsteiner–Wäener (LW) system, 5, 62
Langereis system, 6, 64
Leα, Leβ, 59–61, 60, 60
Lewis system, 5, 59–61, 60, 60
carbohydrate structures, 60
phenotypes and genotypes, 59, 60
LISS see low ionic strength saline
(LISS)
low ionic strength saline (LISS)
addition/reagent cells, 15
definition, 9
IAT, 16
serum-to-cell ratio, 10, 15, 18
Luα, Luβ, 61
Lutheran system, 5, 61
Luαγ, Luαδ, 61
LWα, LWβ, 62
LW system see Landsteiner–Wiener
(LW) system
M, N, 56
MAC see membrane attack complex
(MAC)
macrocomplex of proteins, 38–9, 39,
57–9, 58, 62
malaria
ABO, 34
Duffy glycoprotein, 54
MAM, 64
manual methods, routine blood
  grouping, 8, 19
MAR, 46
‘massive transfusion’, 107–8
McLeod syndrome and phenotype, 52
membrane attack complex (MAC), 11,
  12, 65, 66
Miltenberger series, 57
‘mimicking’ antibodies, 19
MNS system, 5, 56–57
  anti-Mur, 57
  anti-U, 57
  GYP A and GYP B, 57
  M (MNS1) and N (MNS2), 56
  phenotype frequencies, Caucasians,
  56
  S (MNS3) and s (MNS4), 56–57
  S– s– U– phenotype, 57
molecular blood group genotyping, 21,
  81–84
monoclonal antibodies, 67
monocyte monolayer assay, 78
Mur, 57

ear miss events, 109–110
neuraminidase, 12
next-generation sequencing (NGS), 84
NISS see normal ionic strength saline
  (NISS)
NOR, 61
normal ionic strength saline (NISS), 15
  ‘no-wash’ technique, 16–17, 17

obstetric haemorrhage, 107
Ok system, 6

P1 antigen, 61
papain, 12, 101
paroxysmal cold haemoglobinuria
  (PCH), 77
PBS see phosphate buffered saline
  (PBS)
PCH see paroxysmal cold
  haemoglobinuria (PCH)
pH, antigen-antibody reactions, 9
phagocytosis, 72–4, 78
phosphate buffered saline (PBS), 9, 107
polyclonal antibodies, 66
Pk antigen, 61
PI PK system, 5, 61

QA see quality assurance (QA)
quality assurance (QA)
  checklist, critical control, 89
  controls
    laboratory, critical control, 89
    routine laboratory procedures, 86,
    86
  definition, 85
  laboratory errors, RCA and CAPA
    ‘fishbone’ analysis, 90, 90–91
    pre-transfusion testing, 89
    recognition, mixed-field reactions,
    90
    task-based errors, 91
  laboratory, review and approval, 86,
  88
  requirements, transfusion practice,
  88
  total quality management (TQM), 85

Raph system, 6
RCA see root cause analysis (RCA)
reference laboratory see trouble-
  shooting and problem-solving,
  reference laboratory
REIT, 64
RHAG system, 6, 38
RhAG see Rh-associated glycoprotein
  (RhAG)
Rh-associated glycoprotein (RhAG),
  38–39, 39
  function, 47–8
  mutations, 47
Rh blood group system
anomalies, 94, 96–7
biochemistry and molecular genetics
  RHD and RHCE genes, 37, 38
  homology model, 37, 39
  model, membrane complexes, 39, 39
  RhAG, 38–9
C, c, E and e antigens (RH2, RH4, RH3, RH5), 44–5, 45
clinical significance, 42–3, 45
compound antigens, 46
Cw, Cx and MAR (RH8, RH9, RH51), 46
D antigen (RH1), 40–4
D polymorphism, 40
D variants, 41–2, 42, 103
function, 47–8
grouping, 94, 102–3
discrepancies, 95, 96–97
haplotype frequencies, 36
haplotypes, genotypes and phenotypes, 36, 36–7
history, 35–36
Rh-deficient phenotypes (Rhnull and Rhmod), 47
VS and V (RH20, RH10), 46–7
Rh-deficient phenotypes (Rhnull and Rhmod), 47
RhD positive women, pregnancy, 104
U antigen, 57
urea transporter, 55–6
S, s antigens 56–7
SARA, 64
Scianna system, 61
sensitivity vs. specificity, 102
sickle cell disease, 83
single nucleotide polymorphism (SNPs), 82, 83
SMIM1 gene, 64
SNPs see single nucleotide polymorphism (SNPs)
solid-phase microplate methods, 16, 17
spin-tube techniques, 14, 16, 17, 103–4
T antigen, 13
techniques, blood grouping
antigen–antibody reactions, 8–10
automation, test procedures, 19
elution, 18–9
flow cytometry, 19–21
haemagglutination see haemagglutination, reactions
molecular blood group genotyping, 21, 81–4
temperature, antigen-antibody reactions, 8–9
total quality management (TQM), 85, 90
TQM see total quality management (TQM)
transplantation, ABO, 26–7
trouble-shooting and problem-solving, reference laboratory
ABO groups, 92–4
problems and observations,
antibody investigations, 98, 98–9
reaction patterns and tests, antibody specificity, 98, 99–100
Rh grouping, 94–5
tests, antibody determination, 98, 101
V, VS, 46–7
Vel, 64
von Willebrand factor (vWF), 34
total quality management (TQM)
transplantation, ABO, 26–7

WAIHA see Warm antibody immune haemolytic anaemia (WAIHA)
Warm antibody immune haemolytic anaemia (WAIHA), 77
weak D, 41
weight-for-volume method, 13

Wu, 59
Xgα, 61
Xg system, 4, 5, 61
XX gene, 52
Ytα, Ytβ, 61
Yt system, 5, 61

Xga, 61
Xk gene, 52

Wu, 59
Xgα, 61
Xg system, 4, 5, 61
XX gene, 52
Ytα, Ytβ, 61
Yt system, 5, 61